Parneet Cheema

机构：University of Toronto, William Osler Health System · ORCID：0000-0002-9680-7073

发表论文 148 篇 · 总被引 7736 次 · h-index 33

代表论文

• Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer (2024 · New England Journal of Medicine · 被引 227)
• Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer (2024 · Journal of Clinical Oncology · 被引 155)
• Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial (2024 · Nature Medicine · 被引 127)
• Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study (2024 · Journal of Clinical Oncology · 被引 126)
• Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study (2025 · Annals of Oncology · 被引 20)
• Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors (2024 · Current Oncology · 被引 16)